Gsk (GLAXF) Change in Receivables (2011 - 2013)
Gsk (GLAXF) recorded quarterly Change in Receivables of $16.2 million in Q4 2013, down 78.55% quarter-over-quarter from $75.5 million in Q4 2012, and down 78.55% on a YoY basis from $75.5 million in Q4 2012.
Gsk (GLAXF) Change in Receivables (2011 - 2013) Analysis & Trends
Gsk's Change in Receivables history runs 3 years deep, the most recent figure standing at $16.2 million for Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 595.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -87.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -413.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -134.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.69 Bn |
| 10 | Gsk | - | - | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 16.19 Mn |
| Dec 31, 2013 | 16.19 Mn |
| Dec 31, 2012 | 75.48 Mn |
| Dec 31, 2012 | 75.48 Mn |
| Dec 31, 2011 | -42.43 Mn |
| Dec 31, 2011 | -42.43 Mn |